Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.Explore and learn more about Conference Series : World's leading Event Organizer
Non-alcoholic fatty liver disease
As per available reports about 8 relevant journals, 13 Conferences, 28 workshops are presently dedicated exclusively to Non-alcoholic fatty liver disease and about 64 articles are being published on breathing disorder.
Non-alcoholic fatty liver disease is a term used to describe the accumulation of fat in the liver of people who drink little or no alcohol. Non-alcoholic fatty liver disease is common and, for most people, causes no signs and symptoms and no complications. But in some people with non-alcoholic fatty liver disease, the fat that accumulates can cause inflammation and scarring in the liver. This more serious form of non-alcoholic fatty liver disease is sometimes called non-alcoholic steatohepatitis. 3rd World Congress on Hepatitis and Liver Diseases consist of following tracks Hepatitis : Care and Cure, HBV : From Discovery to Cure, Latest advances in the treatment of HCV, Hepatitis Vaccination, Advance Technologies for the Diagnosis and Treatment of Liver Diseases
OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.
Scope and Importance:
Non-alcoholic liver {disease} disease (NAFLD) is one reason behind a liver disease, occurring once fat is deposited (steatosis) within the liver undue to excessive alcohol use. Advancement of NASH may be the consequence of 2 liver abuses. With the beginning affront, macrovesicular steatosis happens which an appearance of inordinate triglyceride is amassing in the liver. Insulin safety and resulting hyperinsulinemia seem to prompt changes in the hepatic pathways of uptake, union, debasement, and emission of free unsaturated fats and eventually to collection of lipids in the hepatocytes. These progressions appear to make the liver defenseless to a second affront, bringing about an incendiary reaction and movement of liver harm. Oxidative anxiety, fundamentally created by mitochondrial brokenness, and pro-inflammatory cytokines (TNF-alpha), are accepted to assume a vital part in the movement of liver harm in NAFLD. Potential oxidative stressors incorporate hepatic iron, leptin, cell reinforcement lacks, and intestinal microscopic organisms.
The liver is a large, meaty organ that sits on the right side of the belly. Weighing about 3 pounds, the liver is reddish-brown in colour and feels rubbery to the touch. Normally you can't feel the liver, because it's protected by the rib cage. The liver's main job is to filter the blood coming from the digestive tract, before passing it to the rest of the body. The liver also detoxifies chemicals and metabolizes drugs. As it does so, the liver secretes bile that ends up back in the intestines. The liver also makes proteins important for blood clotting and other functions. Liver conditions include Hepatitis, Cirrhosis, Liver cancer and Liver failure, Ascites, Gallstones and Hemochromatosis.
Market Analysis:
In 2009, the global market for drugs used to treat liver disease was worth approximately $12.4 billion. Sales in 2010 decreased and the market did not see much progress, causing overall global sales to remain stagnant at $12.4 billion. The market is expected to rise at a CAGR of 3.3% and reach nearly $14.2 billion by 2016. The global liver disease therapeutics market totalled nearly $24.5 billion in 2014 and is projected to approach $33.8 billion by 2019, registering a compound annual growth rate (CAGR) of 6.7% through 2019.
International symposium and workshops
15th international symposium on viral hepatitis and liver disease June 26-28, 2015, Berlin Germany
6th International Symposium on Albumin Dialysis, August 28 – 30, 2015, Rostock-Warnemünde.
List of Best International Conferences:
Relevant Society and Associations
Companies
This page will be updated regularly.
This page was last updated on December 23, 2024
